We can trace our site's history back to the 1980s when there were just ten employees and one production machine in Runcorn.
Teva Runcorn was founded in 1980. Back then, we made wound irrigation bottles for hospital use. We became part of Ivax in 1992 and then Teva in 2006. During this time we have been on a huge journey with the aim of differentiating ourselves from other companies like ours, finding our niche, not only in terms of the medicinal products we produce, but also how our business works.
Originally named Steripak, the business was started in 1980 by John & Ernest Prebble, with a 49% share, and Schering AG, with a 51% share, and the objective was to become the major European Pharmaceutical contract manufacturer for sterile liquids using the process of Blow Fill Seal (BFS).
In 1985 Schering AG acquired the whole company and used the platform to launch its UK business.
In 1987 Waverley Pharmaceuticals acquired the whole share capital of Steripak from Schering AG, a company with staff experienced in the manufacturing of BFS products. The first batch of products was produced in October 1987. At that point, there were 34 people employed. Within two years, this increased to over 200 employees.
In 1992, Steripak was bought by the IVAX Corporation of Miami and became part of the Norton Healthcare Group of Companies. Norton Healthcare specialised in the manufacture of generic pharmaceutical products.
In October 2001 the Norton Healthcare Group changed its name and became IVAX Pharmaceuticals UK Ltd.
In January 2006, the IVAX corporation was acquired by Teva Pharmaceutical industries (headquartered in Israel).
Teva was founded in 1901 and by the 1990s its worldwide presence was established. In the 2000s Teva became one of the top 20 global pharmaceutical companies and by 2006 became the world's largest generic pharmaceutical company. Currently, there are around 50,000 Teva employees working to improve health and enable better days.
Teva develops, produces and markets affordable generic medicines, as well as innovative and specialty pharmaceuticals and over-the-counter consumer healthcare products, along with supplying active pharmaceutical ingredients to nearly 1,000 customers in over 100 countries.
We moved into our current Runcorn site in 2006 and we created a long-term business strategy to help us meet the needs of our patients in the future.
Our talent for innovation reached an exciting milestone in 2009 when we were proud to open our new production line dedicated to making Prefilled Syringe (PFS) medicines such as Teva’s innovative medicine Copaxone® (glatiramer acetate). Copaxone® is used to treat multiple sclerosis (MS) a condition affecting the central nervous system, that means it affects your nerves and it’s caused when your immune system isn’t working properly.
Our colleagues are our greatest asset and key to our success, so in 2010 (the year we began to manufacture budesonide) we created an apprenticeship program to nurture and grow new talent. Our graduate internship program followed in 2012 as we continued to grow and improve our facilities and outputs.